[go: up one dir, main page]

WO2010079340A3 - Methods for identifying compounds modulating type-i transmebrane matrix metalloproteinase (mmp) - Google Patents

Methods for identifying compounds modulating type-i transmebrane matrix metalloproteinase (mmp) Download PDF

Info

Publication number
WO2010079340A3
WO2010079340A3 PCT/GB2010/000031 GB2010000031W WO2010079340A3 WO 2010079340 A3 WO2010079340 A3 WO 2010079340A3 GB 2010000031 W GB2010000031 W GB 2010000031W WO 2010079340 A3 WO2010079340 A3 WO 2010079340A3
Authority
WO
WIPO (PCT)
Prior art keywords
mmp
matrix metalloproteinase
identifying compounds
transmebrane
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2010/000031
Other languages
French (fr)
Other versions
WO2010079340A2 (en
Inventor
Adam Kline
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0900261A external-priority patent/GB0900261D0/en
Priority claimed from GB0900262A external-priority patent/GB0900262D0/en
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of WO2010079340A2 publication Critical patent/WO2010079340A2/en
Publication of WO2010079340A3 publication Critical patent/WO2010079340A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to a method for identifying compounds that act as enhancers or inhibitors of matrix metalloproteinase (MMP) activity. The invention also relates to a method for diagnosing whether or not a subject is at risk of developing, or has, a disease associated with pathogenic APP processing. The invention further relates to the use of type I transmembrane protease inhibitors, in particular inhibitors of MMP 16, MMP 14 or MMP 15 activity, for preventing or treating diseases associated with pathogenic APP processing, such as Alzheimer's disease.
PCT/GB2010/000031 2009-01-08 2010-01-08 Assay Ceased WO2010079340A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0900262.7 2009-01-08
GB0900261A GB0900261D0 (en) 2009-01-08 2009-01-08 Assay
GB0900261.9 2009-01-08
GB0900262A GB0900262D0 (en) 2009-01-08 2009-01-08 Assay

Publications (2)

Publication Number Publication Date
WO2010079340A2 WO2010079340A2 (en) 2010-07-15
WO2010079340A3 true WO2010079340A3 (en) 2010-11-25

Family

ID=42234851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/000031 Ceased WO2010079340A2 (en) 2009-01-08 2010-01-08 Assay

Country Status (1)

Country Link
WO (1) WO2010079340A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9222947B2 (en) 2012-02-03 2015-12-29 Shionogi & Co., Ltd. Anti-sAPPβ antibody

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104769112A (en) 2012-11-01 2015-07-08 菲克特生物科学股份有限公司 Methods and products for expressing proteins in cells
JP6076076B2 (en) * 2012-12-21 2017-02-08 日東電工株式会社 Tissue regeneration promoter

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1118622A1 (en) * 1998-09-29 2001-07-25 Kyowa Hakko Kogyo Co., Ltd. Novel antibodies, drugs containing these antibodies and methods for screening compounds by using these antibodies
EP1136549A1 (en) * 1998-09-29 2001-09-26 Motoharu Seiki Dnas encoding novel polypeptides
WO2001090326A2 (en) * 2000-05-22 2001-11-29 Pharmacia & Upjohn Company Novel matrix metalloproteinases
US20070066527A1 (en) * 2005-09-07 2007-03-22 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5024841A (en) 1988-06-30 1991-06-18 Collagen Corporation Collagen wound healing matrices and process for their production
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
GB0700645D0 (en) 2007-01-12 2007-02-21 Eisai London Res Lab Ltd Targets for disease therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1118622A1 (en) * 1998-09-29 2001-07-25 Kyowa Hakko Kogyo Co., Ltd. Novel antibodies, drugs containing these antibodies and methods for screening compounds by using these antibodies
EP1136549A1 (en) * 1998-09-29 2001-09-26 Motoharu Seiki Dnas encoding novel polypeptides
WO2001090326A2 (en) * 2000-05-22 2001-11-29 Pharmacia & Upjohn Company Novel matrix metalloproteinases
US20070066527A1 (en) * 2005-09-07 2007-03-22 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9222947B2 (en) 2012-02-03 2015-12-29 Shionogi & Co., Ltd. Anti-sAPPβ antibody

Also Published As

Publication number Publication date
WO2010079340A2 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
MX2020010947A (en) Methods of treating alzheimer's disease.
WO2009059150A3 (en) Biomarkers for fatty liver disease and methods using the same
MA35096B1 (en) Cyclopropylamines as lsd1 inhibitors
NO20083002L (en) Method for using CD40 binding compounds
MY156274A (en) COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION
MY177564A (en) Anti-nr10 antibody and use thereof
CO6351728A2 (en) METHODS TO TREAT TALASEMIA
MX2009012950A (en) Humanized antibodies to aãŸ(20-42) globulomer and uses thereof.
GEP20166554B (en) Nitrogenated heterocyclic compound
WO2007098099A3 (en) Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor
UA111861C2 (en) Aromatic heterocyclic dihydroxy compound
EA201390704A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
EA200802054A1 (en) ENZYME INHIBITORS
HK1218576A1 (en) Tuberculosis biomarkers and uses thereof
WO2011002834A3 (en) Compositions and methods for diagnosis and treatment of type 1 diabetes
EA201291413A1 (en) DERIVATIVES 3-AMINO-5,6-DIHYDRO-1H-PYRAZIN-2-SHE, APPLICABLE FOR THE TREATMENT OF ALCHEIMER'S Disease And Other Forms Of Dementia
WO2010059242A3 (en) Neurodegenerative disease diagnostic compositions and methods of use
WO2012078623A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
MX2010001657A (en) Regulators of mmp-9 and uses therof.
MY154715A (en) Anti-nr10 antibody and use thereof
MX2010000956A (en) Compounds which inhibit beta-secretase activity and methods of use thereof.
WO2014100602A8 (en) Treatment of egf-receptor dependent pathologies
WO2010079340A3 (en) Methods for identifying compounds modulating type-i transmebrane matrix metalloproteinase (mmp)
MX2014000113A (en) Compounds for treating peripheral neuropathies and other neurodegenerative disorders.
EA201390876A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10700447

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10700447

Country of ref document: EP

Kind code of ref document: A2